TPG GP A, LLC Acquires 12.6% Stake in Achieve Life Sciences, Inc. via Private Placement

TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, filed a Schedule 13D reporting a new 12.6% stake in Achieve Life Sciences, Inc. (ACHV). The reporting persons acquired 6,877,580 shares of common stock and 6,877,580 warrants through a Securities Purchase Agreement dated April 15, 2026, for an aggregate purchase price of approximately $25 million. The warrants are exercisable at $3.51 per share and have a term linked to the FDA approval of cytisinicline. As part of the agreement, Lucian Iancovici was appointed to the Issuer's Board of Directors. TPG GP A, LLC exercises control over TPG LSI Rise Auriga L.P., the direct holder of the securities. The acquisition was funded by equity contributions from the limited partners of TPG Auriga. The reporting persons have entered into a registration rights agreement to facilitate the resale of the shares and those underlying the warrants. Currently, the filers do not have additional plans for extraordinary corporate transactions but reserve the right to suggest changes to management or capital structure.